Equities research analysts at HSBC initiated coverage on shares of Genus (LON:GNS) in a research note issued to investors on Tuesday. The brokerage set a “buy” rating and a GBX 2,650 ($34.63) price target on the stock. HSBC’s target price suggests a potential upside of 15.02% from the stock’s previous close.
Several other research analysts have also recently commented on the company. Peel Hunt reiterated a “buy” rating on shares of Genus in a research note on Friday, February 1st. Liberum Capital reissued a “hold” rating on shares of Genus in a report on Friday, December 7th. Finally, Kepler Capital Markets raised Genus to a “buy” rating and boosted their price objective for the company from GBX 2,475 ($32.34) to GBX 2,630 ($34.37) in a report on Thursday, December 6th. Two research analysts have rated the stock with a hold rating and three have given a buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of GBX 2,416 ($31.57).
LON:GNS opened at GBX 2,304 ($30.11) on Tuesday. Genus has a one year low of GBX 1,652 ($21.59) and a one year high of GBX 2,597 ($33.93).
Genus plc operates as an animal genetics company in North America, Latin America, rest of Europe, the Middle East, Africa, and Asia. The company operates through three segments: Genus PIC, Genus ABS, and Research and Development. It sells sows, boars, and semen to breed pigs with various characteristics for pork production under the PIC brand.
Recommended Story: What do I need to know about analyst ratings?
Receive News & Ratings for Genus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genus and related companies with MarketBeat.com's FREE daily email newsletter.